CD73: An emerging checkpoint for cancer immunotherapy

Siqi Chen, Derek A. Wainwright, Jennifer D. Wu, Yong Wan, Daniela E. Matei, Yi Zhang, Bin Zhang

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.

Original languageEnglish (US)
Pages (from-to)983-997
Number of pages15
JournalImmunotherapy
Volume11
Issue number11
DOIs
StatePublished - Jan 1 2019

Keywords

  • CD73
  • adenosine receptor
  • immune checkpoint blockade
  • immunotherapy
  • tumor evasion

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'CD73: An emerging checkpoint for cancer immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Chen, S., Wainwright, D. A., Wu, J. D., Wan, Y., Matei, D. E., Zhang, Y., & Zhang, B. (2019). CD73: An emerging checkpoint for cancer immunotherapy. Immunotherapy, 11(11), 983-997. https://doi.org/10.2217/imt-2018-0200